source
- Analysts spot several biotech firms as likely M&A targets amid rising pharma deal activityPharma companies are actively looking for acquisition opportunities, and analysts have identified a handful of biotech firms that could be next in line for buyouts. Recent transactions have center…
- Gilead's HIV prevention shot Yeztugo posts $232 million Q2 sales, beating forecastsGilead reported that its biannual injectable for HIV pre‑exposure prophylaxis, Yeztugo, generated $232 million in revenue during the second quarter. This figure exceeds analysts' consensus estimat…